evonetix is a technology company.
evonetix has raised $66.0M across 3 funding rounds.
evonetix has raised $66.0M in total across 3 funding rounds.
evonetix has raised $66.0M in total across 3 funding rounds.
evonetix's investors include Matt Ocko, Dimension Capital, First Round Capital, Foresite Capital, Krishna Yeshwant, IA Ventures, K9 Ventures, Lux Capital, Northpond Ventures, Recode Ventures, Uncork Capital, UpHonest Capital.
Evonetix is a Cambridge, UK-based synthetic biology company developing a benchtop desktop platform for scalable, high-fidelity, and rapid gene-length DNA synthesis using semiconductor chips.[1][2][3] The platform integrates DNA synthesis, on-chip assembly via its proprietary Binary Assembly® process, and error correction, enabling researchers to produce accurate long DNA sequences without time-consuming post-synthesis steps.[2][4] It serves academic labs, biotech firms, and industries like healthcare, agriculture, and biomaterials, solving key bottlenecks in synthetic biology such as slow speed, high error rates, and limited scalability in current DNA synthesis methods.[1][2][5] This positions Evonetix to accelerate applications like personalized therapies, mRNA vaccines, pest-resistant crops, and novel biomaterials, with recent milestones including its first external platform placement at Imperial College London in preparation for commercialization.[5]
Evonetix was founded in 2015 by Cambridge Consultants and Providence Investment Company Limited to leverage scalable silicon chip manufacturing for benchtop DNA synthesis, marking a shift toward third-generation gene synthesis technology.[3] The idea emerged from recognizing synthetic biology's potential in personalized medicine and beyond, but hindered by first- and second-generation synthesis limitations in accuracy, length, and speed.[1][4] Early traction built through strategic partnerships: in 2018 with LioniX International for high-throughput silicon arrays; in 2020 with imec for commercial-scale MEMS chip production and Analog Devices for biosensor, MEMS, and semiconductor expertise to develop its DNA desktop writer.[3][4] A pivotal 2022 patent (EP3551331B1) for thermal control technology solidified its IP foundation, humanizing its mission to democratize DNA synthesis for global researchers.[3]
Evonetix stands out in gene synthesis through semiconductor-scale innovation:
Evonetix rides the explosive growth of synthetic biology, a multibillion-dollar market fueled by demands for precision medicine, cell therapies, mRNA vaccines, and engineered crops amid global challenges like pandemics and food security.[1][2][4] Timing is ideal post-COVID, as nucleic acid tech proved vital yet was bottlenecked by DNA access—Evonetix's third-generation platform addresses this by enabling on-demand, decentralized synthesis, akin to how semiconductors revolutionized computing.[1][6] Market forces favoring it include advances in MEMS/semiconductors, AI-driven bioengineering, and biofoundry automation, positioning it to capture share in a field where current methods limit innovation.[2][5] By empowering labs worldwide, Evonetix influences the ecosystem, accelerating discoveries in cancer therapies, drought-resistant agriculture, and biomaterials while fostering open synthetic biology research.[2]
Evonetix is poised for commercialization with its first external platform deployed and manufacturing partnerships scaled, likely launching its DNA writer soon to transform lab workflows.[5][9] Trends like enzymatic synthesis breakthroughs, AI-optimized bio-design, and decentralized biomanufacturing will propel it, potentially expanding to industrial-scale applications in personalized medicine and agrotech.[2][9] Its influence may evolve from pioneer to ecosystem enabler, licensing chips or powering biofoundries, ultimately making gene synthesis as routine as PCR—directly advancing the lifesaving solutions that define its Cambridge origins.[1][5]
evonetix has raised $66.0M across 3 funding rounds. Most recently, it raised $24.0M Series B in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $24.0M Series B | Matt Ocko, Dimension Capital, First Round Capital, Foresite Capital, Krishna Yeshwant, IA Ventures, K9 Ventures, Lux Capital, Northpond Ventures, Recode Ventures, Uncork Capital, UpHonest Capital, Y Combinator, Nat Goldhaber | |
| Mar 1, 2020 | $30.0M Series B | ACME Capital, Balderton Capital, Band of Angels, Matt Ocko, Dimension Capital, First Round Capital, Foresite Capital, Krishna Yeshwant, IA Ventures, K9 Ventures, Lux Capital, MassMutual Ventures, Molten Ventures, Northpond Ventures, Recode Ventures, Scalebridge Capital, Uncork Capital, UpHonest Capital, Y Combinator, Esther Dyson, Nat Goldhaber, Richard De Silva | |
| Jan 1, 2018 | $12.0M Series A | ACME Capital, Artis Ventures (AV), Balderton Capital, Band of Angels, Matt Ocko, Dimension Capital, IA Ventures, Lux Capital, MassMutual Ventures, Molten Ventures, Recode Ventures, Scalebridge Capital, UpHonest Capital, Y Combinator, Esther Dyson, Richard De Silva |